ArticleNews reportPHN-04742026-11-01 08:00 CT

Sun Pharma Gets CDSCO Nod for Generic Semaglutide Pill

Source · Medical Dialogues

TLDR

Medical Dialogues reports that Sun Pharma received CDSCO approval to manufacture and market generic oral semaglutide in India for type 2 diabetes. The approval covers three tablet strengths, which the report describes as therapeutically equivalent to Novo’s Rybelsus.

01—Key points

01The reported approval is for type 2 diabetes, not weight management.
02The article says a separate Indian patent still protects the oral formulation despite semaglutide’s patent expiry in March.
03Torrent Pharma and Dr Reddy’s have already introduced generic oral semaglutide brands, according to the report.

Why it matters Editorial

The reported approval adds another company to India’s generic oral semaglutide market amid continuing formulation-patent protections.

Read the original at Medical Dialogues↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.